EE200000147A - April - uus kasvuefekte omav valk - Google Patents

April - uus kasvuefekte omav valk

Info

Publication number
EE200000147A
EE200000147A EEP200000147A EEP200000147A EE200000147A EE 200000147 A EE200000147 A EE 200000147A EE P200000147 A EEP200000147 A EE P200000147A EE P200000147 A EEP200000147 A EE P200000147A EE 200000147 A EE200000147 A EE 200000147A
Authority
EE
Estonia
Prior art keywords
april
new growth
growth protein
protein
new
Prior art date
Application number
EEP200000147A
Other languages
English (en)
Inventor
Tschopp Jurg
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000147A publication Critical patent/EE200000147A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200000147A 1997-09-12 1998-09-11 April - uus kasvuefekte omav valk EE200000147A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US7938498P 1998-03-26 1998-03-26
PCT/US1998/019191 WO1999012965A2 (en) 1997-09-12 1998-09-11 April- a novel protein with growth effects

Publications (1)

Publication Number Publication Date
EE200000147A true EE200000147A (et) 2001-02-15

Family

ID=26738027

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000147A EE200000147A (et) 1997-09-12 1998-09-11 April - uus kasvuefekte omav valk

Country Status (20)

Country Link
US (3) US20030138884A1 (et)
EP (1) EP1027431A2 (et)
JP (1) JP2001515712A (et)
KR (1) KR100618492B1 (et)
CN (1) CN1195849C (et)
AU (1) AU759717B2 (et)
BR (1) BR9812634A (et)
CA (1) CA2303615A1 (et)
CZ (1) CZ294615B6 (et)
EA (1) EA005411B1 (et)
EE (1) EE200000147A (et)
HU (1) HUP0004611A3 (et)
IL (1) IL134537A0 (et)
IS (1) IS5378A (et)
NO (1) NO20001242L (et)
NZ (1) NZ503850A (et)
PL (1) PL339463A1 (et)
SK (1) SK3542000A3 (et)
TR (1) TR200000669T2 (et)
WO (1) WO1999012965A2 (et)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
AU1700999A (en) * 1997-11-26 1999-06-15 Eli Lilly And Company Tnf ligand family gene
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
HUP0105283A3 (en) 1999-01-25 2004-08-30 Biogen Idec Ma Inc Cambridge Baff, inhibitors thereof and their use in the modulation of b-cell response
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
EE05673B1 (et) * 1999-08-17 2013-08-15 Biogen, Inc. BAFF-retseptor (BCMA), immunoregulatoorne agens
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001025256A2 (en) * 1999-10-06 2001-04-12 University Of Utah Research Foundation Trdl-1-gamma, a novel tumor necrosis-like ligand
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
DE60028830T2 (de) * 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
AU2006201471B2 (en) * 2000-02-16 2009-07-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of TNF-related molecules
WO2001087979A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1294949A4 (en) * 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB2370273A (en) * 2000-12-20 2002-06-26 Viaxxel Biotech Gmbh Compounds that affect CD83 expression
CA2446734A1 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
PT1436003E (pt) 2001-05-24 2010-03-12 Zymogenetics Inc Proteínas de fusão imunoglobulina taci
AU2003207464A1 (en) 2002-01-04 2003-07-24 Xencor Dominant negative proteins and methods thereof
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
CA2520097C (en) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Truncated baff receptors
EP1709072A1 (en) * 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005113598A2 (en) * 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
KR20080056714A (ko) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
CA2623530C (en) * 2005-09-26 2015-02-03 Apotech Corporation Antibodies against april as biomarkers for early prognosis of lymphoma patients
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
AU2010220421B9 (en) 2009-03-02 2015-03-05 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (APRIL)
US8981057B2 (en) * 2010-03-05 2015-03-17 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam B-cell stimulating fusion proteins of an antigen with BAFF or APRIL
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
RS64573B1 (sr) * 2013-09-23 2023-10-31 Regeneron Pharma Ne-humana životinja sa humanizovanim signalno-regulatornim proteinskim genom
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
JP6484237B2 (ja) * 2013-11-19 2019-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化増殖誘導リガンド遺伝子を有する非ヒト動物
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN109089419B (zh) 2015-11-25 2024-03-01 威特拉公司 April的抗体分子及其应用
CA3199743A1 (en) 2020-10-29 2022-05-05 Industrial Polymers and Chemicals, Inc. Air filter with pathogen monitoring and inactivation
WO2023019223A2 (en) 2021-08-11 2023-02-16 Akso Biopharmaceutical Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
US6509170B1 (en) * 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
ATE254135T1 (de) * 1996-03-14 2003-11-15 Human Genome Sciences Inc Humaner tumornekrosefaktor delta und epsilon
US6171787B1 (en) * 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease

Also Published As

Publication number Publication date
TR200000669T2 (tr) 2000-08-21
IL134537A0 (en) 2001-04-30
PL339463A1 (en) 2000-12-18
AU759717B2 (en) 2003-04-17
US20060084148A1 (en) 2006-04-20
CZ294615B6 (cs) 2005-02-16
CN1195849C (zh) 2005-04-06
CZ2000869A3 (cs) 2000-09-13
EP1027431A2 (en) 2000-08-16
NZ503850A (en) 2002-12-20
HUP0004611A2 (hu) 2001-04-28
EA200000310A1 (ru) 2000-10-30
AU9316298A (en) 1999-03-29
HUP0004611A3 (en) 2002-04-29
EA005411B1 (ru) 2005-02-24
CA2303615A1 (en) 1999-03-18
US20050112596A1 (en) 2005-05-26
CN1270632A (zh) 2000-10-18
WO1999012965A3 (en) 1999-06-03
IS5378A (is) 2000-02-18
JP2001515712A (ja) 2001-09-25
SK3542000A3 (en) 2000-08-14
NO20001242D0 (no) 2000-03-09
KR100618492B1 (ko) 2006-08-31
US20030138884A1 (en) 2003-07-24
NO20001242L (no) 2000-05-11
BR9812634A (pt) 2000-08-22
KR20010023893A (ko) 2001-03-26
WO1999012965A2 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
EE200000147A (et) April - uus kasvuefekte omav valk
NO983364L (no) Konsensusproteiner
DE59806239D1 (de) Mähdrescher
NO2010022I1 (no) Denosumab
DE69839603D1 (de) Zierenden proteins
DE69820156D1 (de) VErbessertes monofilament
DE69824232D1 (de) Gefriergerät
DE59706733D1 (de) Erntemaschine
DK0832553T3 (da) Mejetærsker
DE69802241D1 (de) Mähmaschine
DE59705517D1 (de) Mähdrescher
FR2747908B1 (fr) Suture irrigatrice
ID22391A (id) Alat pendingin
DE69925271D1 (de) Angiostatin-bindendes protein
TR199701666A3 (tr) Sismanliga karsi proteinler
DE59808209D1 (de) Mähdrescher
DE69704693D1 (de) Mähdrescher
DE59809449D1 (de) Mähdrescher
DE69636232D1 (de) Wachstumsfaktor htter36
ATA126198A (de) Mähwerk
DE69801101D1 (de) Kraftzange
DK1088069T3 (da) Angiostatin-bindende protein
SE9802189D0 (sv) New Proteins
KR970056464U (ko) 개량 낚시
FI3923U1 (fi) Karsimiskone

Legal Events

Date Code Title Description
HC1A Change of owner name